Intersect ENT, Inc. (XENT) Scheduled to Post Earnings on Tuesday
Intersect ENT, Inc. (NASDAQ:XENT) will be releasing its earnings data after the market closes on Tuesday, October 31st. Analysts expect Intersect ENT to post earnings of ($0.20) per share for the quarter.
Intersect ENT (NASDAQ:XENT) last released its quarterly earnings results on Tuesday, August 1st. The medical equipment provider reported ($0.08) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.19) by $0.11. The business had revenue of $24.00 million during the quarter, compared to analyst estimates of $22.62 million. Intersect ENT had a negative net margin of 22.94% and a negative return on equity of 17.60%. The business’s revenue was up 24.4% on a year-over-year basis. During the same period last year, the business earned ($0.21) EPS. On average, analysts expect Intersect ENT to post $-0.61 EPS for the current fiscal year and $-0.39 EPS for the next fiscal year.
Shares of Intersect ENT, Inc. (NASDAQ XENT) opened at 30.00 on Tuesday. The firm’s market capitalization is $875.67 million. Intersect ENT, Inc. has a 12-month low of $7.65 and a 12-month high of $33.25. The company’s 50-day moving average is $30.02 and its 200-day moving average is $26.80.
A number of equities analysts have recently commented on XENT shares. BidaskClub lowered shares of Intersect ENT from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, July 25th. Canaccord Genuity reaffirmed a “buy” rating and set a $32.00 target price on shares of Intersect ENT in a research report on Wednesday, August 2nd. Deutsche Bank AG set a $31.00 target price on shares of Intersect ENT and gave the stock a “buy” rating in a research report on Wednesday, August 2nd. Zacks Investment Research raised shares of Intersect ENT from a “hold” rating to a “buy” rating and set a $33.00 target price on the stock in a research report on Thursday, October 5th. Finally, Bank of America Corporation boosted their target price on shares of Intersect ENT from $33.00 to $40.00 and gave the stock a “buy” rating in a research report on Monday, September 11th. Four analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $27.70.
In other Intersect ENT news, COO Richard E. Kaufman sold 22,425 shares of Intersect ENT stock in a transaction on Monday, August 28th. The shares were sold at an average price of $30.22, for a total transaction of $677,683.50. Following the sale, the chief operating officer now owns 149,821 shares in the company, valued at $4,527,590.62. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Lisa D. Earnhardt sold 20,000 shares of Intersect ENT stock in a transaction on Tuesday, August 15th. The stock was sold at an average price of $30.79, for a total transaction of $615,800.00. Following the sale, the insider now owns 525,868 shares in the company, valued at approximately $16,191,475.72. The disclosure for this sale can be found here. Insiders have sold 134,563 shares of company stock worth $4,014,904 in the last quarter. Corporate insiders own 13.70% of the company’s stock.
WARNING: “Intersect ENT, Inc. (XENT) Scheduled to Post Earnings on Tuesday” was reported by American Banking News and is the property of of American Banking News. If you are accessing this piece on another website, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be read at https://www.americanbankingnews.com/2017/10/24/intersect-ent-inc-xent-scheduled-to-post-earnings-on-tuesday.html.
About Intersect ENT
Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.
Receive News & Ratings for Intersect ENT Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT Inc. and related companies with MarketBeat.com's FREE daily email newsletter.